Budget Bill Makes End Run Around Medicare Payment Policy For Omidria, Amyvid
Executive Summary
Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.
You may also be interested in...
No Deal: Omnibus Spending Bill Moves Without Part D Discount Relief
Biopharma lobbying to include provision to reduce the 70% discount on brands in the budget bill runs out of time, leaving industry evaluating other possible legislative vehicles.
FDA OK's Omeros cataract surgery drug Omidria; eyes on pricing
With the FDA's approval in hand for Omidria (phenylephrine and ketorolac injection) for use during cataract surgery or intraocular lens replacement (ILR), all eyes are now on the drug's pricing and launch, which is anticipated late summer or early fall.
CMS’ Amyvid Final NCD Clarifies Trial Outcomes Goals
Agency’s final national coverage determination for beta amyloid positron emission tomography in diagnosing dementia confirms stance the diagnostic will be covered only in trial setting for Medicare, but may offer a little more flexibility in trial design.